{Reference Type}: Letter
{Title}: [New drug arrival : Pembrolizumab as second-line treatment in MSI-H/dMMR endometrial, colorectal, gastric, intestinal and biliary cancers].
{Author}: El-Ghazzi N;Rousseau B;Rodrigues M;
{Journal}: Bull Cancer
{Volume}: 110
{Issue}: 1
{Year}: 01 2023
{Factor}: 1.318
{DOI}: 10.1016/j.bulcan.2022.10.003
{Abstract}: